Capsaicin 8% cutaneous patch (Qutenza) is used to treat peripheral neuropathy (PN) in adults. Qutenza was approved in May 2009 for the treatment of non-diabetic adults with PN. In September 2015 the licence was extended to include diabetic patients. This review presents the evidence which supports this licence variation.
NOTE: The content of this resource has not been updated since the publication date. Some information may be out of date and links to other documents or website may not work.